The global epilepsy monitoring devices market is projected to reach USD 615 million by 2026 from USD 489 million in 2021, at a CAGR of 4.7% during the forecast period. The growth in this market is driven by the increasing incidence and prevalence of epilepsy, growing preference for ambulatory healthcare and increasing use of wearables, growing demand for continuous monitoring, and the rising awareness of neurodegenerative diseases, including epilepsy.
Natus Medical, Inc. (US), Compumedics Limited (Australia), The Magstim Co. Ltd. (UK), Nihon Kohden Corporation (Japan), and Masimo Corporation (US) were the top players in the epilepsy monitoring devices market during the forecast period. Other major players in the market include Empatica, Inc. (US), Medtronic Plc (Ireland), Boston Scientific Corporation (US), Drägerwerk AG & Co. KGaA (Germany), mjn Neuroserveis S.L. (Spain), Abbott Laboratories, Inc. (US), LivAssured B.V. (Netherlands), BioSerenity (France), Aleva Neurotherapeutics (Switzerland), Medpage, Ltd. (UK), Neurosoft (Russia).